Adaptive Biotechnologies Q4 revenue beats estimates

Overview

• Biotechnology firm's Q4 revenue rose 51% yr/yr, beating analyst expectations

• Adjusted EBITDA for Q4 turned positive, exceeding analyst estimates

• MRD business achieved positive adjusted EBITDA and cash flow

Outlook

• Adaptive Biotechnologies expects MRD revenue between $255 mln and $265 mln for 2026

• Company projects operating expenses between $350 mln and $360 mln for 2026

• Adaptive Biotechnologies aims to expand margins and achieve profitability in 2026

Result Drivers

• MRD REVENUE GROWTH - MRD business revenue increased 54% in Q4, contributing 86% of total revenue

• EXPANDED COVERAGE - Expanded Medicare coverage for clonoSEQ test in mantle cell lymphoma

• DATA PARTNERSHIPS - Signed two non-exclusive immune receptor data licensing agreements with Pfizer

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Adaptive Biotechnologies Corp is $20.00, about 15.6% above its February 4 closing price of $17.30

Press Release: ID:nGNXpXjcn

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.